Straits Times Index
3,330.81 +0.80 (+0.02%) S&P 500
5,348.45 -5.58 (-0.10%) Dow
38,856.87 +49.54 (+0.13%) Nasdaq
17,167.46 -20.44 (-0.12%) Bitcoin USD
71,031.20 -478.66 (-0.67%) CMC Crypto 200
1,521.87 -2.93 (-0.19%)
APLS Jan 2026 70.000 call
| Previous close | 5.15 |
| Open | 5.15 |
| Bid | 4.70 |
| Ask | 6.50 |
| Strike | 70.00 |
| Expiry date | 2026-01-16 |
| Day's range | 5.15 - 5.15 |
| Contract range | N/A |
| Volume | |
| Open interest | 353 |
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireApellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. Abou
ZacksApellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
